In this article, we will discuss Durvalumab (Warnings-8). So, let’s get started.
In Patients Who Received Recent Prior Radiation
The incidence of pneumonitis (including radiation pneumonitis) in patients with unresectable Stage III NSCLC following definitive chemoradiation within 42 days prior to initiation of Durvalumab in PACIFIC was 18.3% (87/475) in patients receiving Durvalumab and 12.8% (30/234) in patients receiving placebo. Of the patients who received Durvalumab (475) 1.1% were fatal and 2.7% were Grade 3 adverse reactions. Events resolved in 50 of the 87 patients and resulted in permanent discontinuation in 27 patients.